Revenue and profitability trend drivers:
- Revenue: $123,751 (QQ1 2025) vs. prior-year level, representing a YoY increase of 5.60% and a QoQ increase of 156.39% as per provided metrics. Managed growth was led by distributor sales (+102% YoY to $68,000) and direct clinic sales of $55,000 (down 33% YoY).
- Gross profit and margin: Gross profit $110,757, margin 89.50% (flat YoY margin basis at 89.5% of revenue).
- Operating expenses: Total operating expenses $2,155,189, down 28% YoY due to cost-reduction and restructuring efforts (G&A down by $0.53 million; S&M down by $0.41 million; R&D up by $0.094 million).
- EBITDA and margins: EBITDA is negative at $(2,010,935); EBITDA margin —16.25%. Operating income margin: −16.52%; Net income margin: −16.54%.
- Net income and EPS: Net income of $(2,047,063); basic/diluted EPS of $(0.11).
- Cash flow and liquidity: Net cash used in operating activities $(1,530,469); free cash flow $(1,545,647); cash at period-end $12,414. Post-quarter, the company raised net proceeds of about $1.2 million to bolster growth initiatives. Net cash used for financing activities was $1,470,658, with a small net decrease in cash of $(74,989) for the period. Balance sheet shows total assets $2,888,930 and total liabilities $2,059,427; cash and cash equivalents on hand $12,414; long-term debt $968,246; total debt $1,166,689; retained earnings negative at $(84,846,387).
- Key liquidity takeaway: The company ended the quarter with limited cash on hand but secured additional financing to support near-term growth, a typical dynamic for a development-stage medical device company with an R&D and commercialization-heavy spend profile.